Equity Overview
Price & Market Data
Price: $8.45
Daily Change: -$0.82 / 9.70%
Range: $8.11 - $9.29
Market Cap: $13,904,052
Volume: 97,390
Performance Metrics
1 Week: 7.78%
1 Month: 86.12%
3 Months: 101.2%
6 Months: 42.26%
1 Year: 74.15%
YTD: 63.44%
Company Details
Employees: 7
Sector: Health technology
Industry: Biotechnology
Country: British Virgin Islands
Details
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; and PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors. The company also develops PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials. Portage Biotech Inc. is based in Tortola, British Virgin Islands.